A prospective, non-controlled, pilot, 22-week study will evaluate the safety and efficacy of topical 0.03 % tacrolimus ointment in patients with subepithelial corneal infiltrates (SEIs) in adenoviral keratoconjunctivitis

Trial Profile

A prospective, non-controlled, pilot, 22-week study will evaluate the safety and efficacy of topical 0.03 % tacrolimus ointment in patients with subepithelial corneal infiltrates (SEIs) in adenoviral keratoconjunctivitis

Completed
Phase of Trial: Phase II

Latest Information Update: 17 Dec 2015

At a glance

  • Drugs Tacrolimus (Primary)
  • Indications Infectious keratoconjunctivitis; Keratoconjunctivitis
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 17 Dec 2015 Status changed from not stated to completed.
    • 15 Dec 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top